Cost Effectiveness of Long-Term Incobotulinumtoxin-A Treatment in the Management of Post-stroke Spasticity of the Upper Limb from the Australian Payer Perspective

BACKGROUND: In Australia, the reimbursement of botulinum neurotoxin-A (BoNT-A) on the Pharmaceutical Benefits Scheme for the treatment of moderate to severe spasticity of the upper limb following a stroke (PSS-UL) is restricted to four treatment cycles per upper limb per lifetime. This analysis exam...

Descripción completa

Detalles Bibliográficos
Autores principales: Makino, Koji, Tilden, Dominic, Guarnieri, Carmel, Mudge, Mia, Baguley, Ian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393278/
https://www.ncbi.nlm.nih.gov/pubmed/29915932
http://dx.doi.org/10.1007/s41669-018-0086-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393278/
https://www.ncbi.nlm.nih.gov/pubmed/29915932
http://dx.doi.org/10.1007/s41669-018-0086-z

Ejemplares similares